EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

Toward Hormone-Aware Psychopharmacology: Gender-Specific Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs in Women

Revanda Nafa Mustofa, Reynatha C. A. Pangsibidang, Rinda Dwi Sartika

JURNAL FARMASIMED (JFM) · 30.10.2026 · 9 (1) · 964-972

DOI: 10.35451/jfm.v9i1.3989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JURNAL FARMASIMED (JFM), online erschienen am 30.10.2026. Verfasst von Revanda Nafa Mustofa und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biological sex differences are important determinants of responses to psychotropic drugs. Women exhibit significant pharmacokinetic and pharmacodynamic variability due to fluctuations in reproductive hormones.

Objective

This narrative review aims to analyze the impact of hormonal phases on mental health therapy in women.

Methods

A narrative literature review was conducted on publications from 2021 to 2026.

Results

During the third trimester of pregnancy, plasma concentrations of selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) decrease substantially, by up to 90% for paroxetine, followed by a postpartum rebound that may increase the risk of toxicity. Additionally, estrogen-containing oral contraceptives induce the UGT1A4 enzyme, reducing lamotrigine concentrations by more than 50% and increasing the risk of toxicity during hormone-free intervals. For antipsychotic therapy, women achieve serum drug concentrations 56–72% higher than men at standard doses, increasing the risk of hyperprolactinemia and QT interval prolongation. Furthermore, the underlying mechanisms of premenstrual dysphoric disorder are associated with impaired GABA-A receptor δ-subunit plasticity in response to the neurosteroid allopregnanolone.

Conclusion

Psychopharmacological prescribing for women should adopt a hormone-aware approach, incorporating therapeutic drug monitoring and dose adjustments based on life stages to optimize treatment efficacy and safety.

Zitieren

APA

Mustofa, R. N., Pangsibidang, R. C. A., & Sartika, R. D. (2026). Toward Hormone-Aware Psychopharmacology: Gender-Specific Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs in Women. JURNAL FARMASIMED (JFM), 9(1), 964-972. https://doi.org/10.35451/jfm.v9i1.3989

Vancouver

Mustofa RN, Pangsibidang RCA, Sartika RD. Toward Hormone-Aware Psychopharmacology: Gender-Specific Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs in Women. JURNAL FARMASIMED (JFM). 2026;9(1):964-972. doi:10.35451/jfm.v9i1.3989

BibTeX
@article{Mustofa2026,
  author = {Mustofa, Revanda Nafa and Pangsibidang, Reynatha C. A. and Sartika, Rinda Dwi},
  title = {Toward Hormone-Aware Psychopharmacology: Gender-Specific Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs in Women},
  journal = {JURNAL FARMASIMED (JFM)},
  year = {2026},
  volume = {9},
  number = {1},
  pages = {964--972},
  doi = {10.35451/jfm.v9i1.3989}
}
Kostenlos starten →